Drug Profile
Research programme: cancer vaccine - TuHURA Biosciences
Alternative Names: ImmuneFxLatest Information Update: 15 Mar 2024
Price :
$50
*
At a glance
- Originator Morphogenesis
- Class Cancer vaccines
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Cancer
Most Recent Events
- 28 Jun 2023 No recent reports of development identified for preclinical development in Cancer in USA (IV, Injection)
- 16 Jul 2016 No recent reports of development identified for preclinical development in Cancer in USA (IV, Injection)
- 09 May 2007 Data presented at the 98th Annual Meeting of the American Association for Cancer Research (AACR-2007) added to the adverse events and Cancer immunogenicity sections